Multiple Myeloma
Conditions
Keywords
Relapsed / Refractory Multiple Myeloma, Antibody-Drug Conjugate, belantamab mafodotin, Combination therapy, Belamaf
Brief summary
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone \[Len/Dex (Treatment A)\] or Bortezomib Plus Dexamethasone \[Bor/Dex (Treatment B)\] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Participants receiving treatment A, may continue combination treatment until the occurrence of progressive disease (PD), intolerable adverse events (AEs ), consent withdrawal, death or end of study. The participants receiving treatment B, may continue combination treatment for a total of up to 8 cycles. After 8 cycles of combination therapy, the participants will continue treatment with belantamab mafodotin, as a monotherapy until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study.
Interventions
DRUGBelantamab mafodotin
Selected doses of belantamab mafodotin will be administered as an infusion.
DRUGLenalidomide
Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
DRUGDexamethasone
Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
DRUGBortezomib
Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
Sponsors
Iqvia Pty Ltd
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label study; therefore, no blinding of treatment identity will be done for both treatments.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Capable of giving signed informed consent. * Male or female, 18 years or older (at the time consent is obtained). * Have confirmed diagnosis of Multiple Myeloma (MM) as defined by the IMWG. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 for Arm A and 0 to 2 for Arm B. * Have undergone stem cell transplant (SCT), or are considered transplant ineligible. * Have been previously treated with at least 1 prior line of MM therapy, and must have documented disease progression during or after their most recent therapy. * Must have at least ONE aspect of measurable disease, defined as one the following: Urine M-protein excretion \>=200 milligram (mg)/24 hours, or; Serum M-protein concentration \>=0.5 gram (g)/deciliter (dL) (\>=5.0 g/Liter), or; Serum free light chain (FLC) assay: involved FLC level \>=10 mg/dL (\>=100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65). * Participants with a history of autologous SCT, are eligible for study participation provided the following eligibility criteria are met: Autologous SCT was \>100 days prior to study enrollment; No active bacterial, viral, or fungal infection(s) present; Participant meets the remainder of the eligibility criteria. * All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], Version 4.03, 2010) must be Grade \<= 1 at the time of enrollment, except for alopecia. Participants with Grade 2 neuropathy can be enrolled into Len/Dex treatment arm, but not into Bor/Dex treatment arm. * Adequate organ system functions as defined by the laboratory assessments. * The contraceptions used by female participants be consistent with local regulations, regarding methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (WOCBP) or Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of belantamab mafodotin and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. WOCBP Participants Assigned to Arm A: * Due to lenalidomide being a thalidomide analogue with risk for embryo-fetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, WOCBP participants will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control (one method that is highly effective; beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use a contraceptive method that is highly effective (with a failure rate of \<1% per year) for a further 3 months, and agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period: Two negative pregnancy tests must be obtained prior to initiating lenalidomide therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing lenalidomide therapy. WOCBP Participants Assigned to Arm B * WOCBP assigned to Arm B must have a negative highly sensitive serum pregnancy test within 72 hours of dosing on C1D1 and agree to use effective contraception during the study and for 4 months after the last dose of belantamab mafodotin or 7 months from the last dose of bortezomib, whichever is longer. * Male participants using contraception should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Male participants are eligible to participate if they agree to the following: Arm A: from the time of first dose of study until 6 months after the last dose of belantamab mafodotin 4 weeks after the last dose of lenalidomide, whichever is longer, to allow for clearance of any altered sperm. Arm B: from the time of first dose of study until 6 months after the last dose of belantamab mafodotin or 4 months from the last dose of bortezomib (whichever is the longer) to allow for clearance of any altered sperm. * Male participants must agree to refrain from donating sperm and either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below. * Agree to use a male condom even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse. Male participants should also use a condom with pregnant females. If the female partner of the male participant is pregnant at the time of enrollment, or becomes pregnant during the trial, the male participant must agree to remain abstinent (if it is consistent with their preferred and usual lifestyle) or use a male condom.
Exclusion criteria
* Systemic anti-myeloma therapy (including systemic steroids) within \<=14 days, or plasmapheresis within 7 days prior to the first dose of study drug. * Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug. * Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs. * Prior allogenic stem cell transplant. Note: Participants who have undergone syngeneic transplant will be allowed only if they have no history and no currently active, graft versus host disease (GvHD). * Evidence of active mucosal or internal bleeding. * Any major surgery within the last four weeks. * Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill criteria. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures. * Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease per investigator's assessment). * Participants with invasive malignancies other than multiple myeloma are excluded, unless the second malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. Note: Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction. * Evidence of cardiovascular risk including any of the following: Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the New York Heart Association functional classification system; Uncontrolled hypertension. * Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment. * Pregnant or lactating female. * Active infection requiring treatment. * Known Human immunodeficiency virus (HIV) infection. * Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at Screening or within 3 months prior to first dose of study treatment). * Current corneal disease except for mild punctuate keratopathy. * Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at Screening or within 3 months prior to first dose of study treatment. * Current corneal disease except for mild punctute keratopathy. * Participants Assigned to Treatment A (belantamab mafodotin plus Len/Dex): Participants unable to tolerate antithrombotic prophylaxis must be excluded; Discontinuation of prior treatment with lenalidomide due to intolerable AEs. * Participants Assigned to Treatment B (belantamab mafodotin plus Bor/Dex): Unacceptable AEs from previous bortezomib treatment; Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A | Up to 28 days | DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment). |
| Number of Participants With DLTs, Treatment B | Up to 21 days | DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment). |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to approximately 4.5 years | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary). |
| Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Up to approximately 4.5 years | 12-lead electrocardiogram (ECGs) were obtained using an automated ECG machine that automatically calculated the QTcF intervals. QTc values are categorized into the clinical concern ranges which are specific to changes in QTc: 31-60 milliseconds (msec), and \>60 msec, and \>530msec. An increase is defined relative to Baseline. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Data of number of participants with worst-case increase post baseline is presented. |
| Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 4.5 years | Blood samples were collected for analysis of following hematology parameters: Hemoglobin (hemoglobin increased and anemia), Lymphocytes (lymphocyte count increased and lymphocyte count decreased), Neutrophils, Platelets and Leukocytes (leukocytosis and white blood cells decreased). The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented. |
| Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 4.5 years | Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes, erythrocytes and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. |
| Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 4.5 years | Blood samples were collected for analysis of following clinical chemistry parameters: Hyperglycemia, Hypoglycemia, Albumin, Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase, (AST), Bilirubin, Creatine Kinase (CK), Creatinine, Gamma Glutamyl Transferase (GGT), Hyperkalemia, Hypokalemia, Hypermagnesemia, Hypomagnesemia, Phosphate, Hypernatremia, Hyponatremia, Urate, Hypercalcemia and Hypocalcemia. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented. |
| Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 4.5 years | Blood samples were collected for analysis of following clinical chemistry parameters: Direct Bilirubin (DB), Calcium, Chloride, Carbon Dioxide (CO2), lactate dehydrogenase (LDH) and Protein. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. |
| Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Baseline (Day 1) and up to approximately 4.5 years | Urine samples were collected to analyze presence of occult blood and protein in urine by dipstick method. Data for worst-case post baseline urinalysis results is presented. Result for urinalysis parameters were recorded as no change/decreased and increase to trace, 1+, 2+, 3+, \>3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. |
| Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) and up to approximately 4.5 years | Urine samples were collected to analyze urine pH levels. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. |
| Change From Baseline in Urine Specific Gravity | Baseline (Day 1) and up to approximately 4.5 years | Urine samples were collected to analyze urine specific gravity using dipstick method. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. |
| Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | Baseline (Day 1) and up to approximately 4.5 years | Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. |
| Change From Baseline in Vital Signs : Pulse Rate | Baseline (Day 1) and up to approximately 4.5 years | Pulse rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. |
| Change From Baseline in Vital Signs : Temperature | Baseline (Day 1) and up to approximately 4.5 years | Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. |
| Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | Up to approximately 4.5 years | ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasmacytomas in the bone marrow; sCR: stringent complete response, CR as above plus normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR \>= 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 h. Confidence intervals were based on the exact method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 28 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 29; Pre-Dose and Post-Dose on Week 5 Day 7 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008) was derived only for Belantamab mafodotin 1.9mg/kg + Len/Dex STRETCH cohort. |
| AUC(0-1344h) for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 29; Pre-Dose and Post-Dose on Week 7 Day 7 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1344) was derived only for Belantamab mafodotin 1.9mg/kg + Len/Dex STRETCH cohort. |
| Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 29; pre-dose Cycle 2 Day 28; pre-dose Cycle 3 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups. |
| Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 5 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 5 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 21 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 11; Cycle 1 Day 22; Pre-Dose and Post-Dose on Week 5 Day 7 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008h) was derived only for Belantamab mafodotin 1.9 mg/kg STRETCH + Bor/Dex, Belantamab mafodotin 2.5 mg/kg StepDown STRETCH + Bor/Dex and Belantamab mafodotin 2.5 mg/kg STRETCH + Bor/Dex cohorts. |
| Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 9 Day 1 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups. |
| Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tmax for Lenalidomide (10 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1, and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-336h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 14 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC (0-336h) was derived only for the Belantamab mafodotin 2.5mg/kg + Len/Dex SPLIT cohort. |
| Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 1 Day 15 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 7 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1, Cycle 1 Day 4; and Cycle 1 Day 7 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 2 Day 1 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups. |
| C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 10 Day 8, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Lenalidomide (25 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC(0-24h) for Lenalidomide (25 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-4h) for Lenalidomide (25 mg), Treatment A | Pre-Dose, 0.5, 1, 2 and 4 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tmax for Lenalidomide (25 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Lenalidomide (25 mg), Treatment A | Pre-Dose, Post dose on Cycle 1 Day 1 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Lenalidomide (10 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC(0-24h) for Lenalidomide (10 mg), Treatment A | Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-4h) for Lenalidomide (10 mg), Treatment A | Pre-Dose, 0.5, 1, 2 and 4 hours on Cycle 1 Day 1 post lenalidomide dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Lenalidomide (10 mg), Treatment A | Pre-Dose, Post dose on Cycle 1 Day 1 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Bortezomib, Treatment B | Pre-Dose, 0.5, 1, 2, 4 and 24 Hours Post-Dose on Cycle 1 Day 1 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | Pre-Dose, 0, 2 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for pharmacokinetic (PK) analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-t) for Bortezomib, Treatment B | Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tmax for Bortezomib, Treatment B | Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Bortezomib, Treatment B | Pre-Dose, Post dose on Cycle 1 Day 3 | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Up to approximately 4.5 years (End of Treatment [EoT]) | Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin using validated immunoassays. |
| Titers of ADAs Against Belantamab Mafodotin | Up to approximately 4.5 years | Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin using validated immunoassays. Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented. |
| Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) and up to approximately 4.5 years | The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. OSDI consist of three subscales (ocular symptoms: item 1-3; visual related function: item 4-9; environmental triggers: item 10-12). Each item will be graded on a scale of 0 (none of the time or lower disability) to 4 (all of the time or greater disability) with total scores ranging from 0 (no disability) to 100 (complete disability). The total OSDI score was calculated as (sum of scores for all questions answered\*100) divided by (total number of questions answered\*4). Higher scores indicated greater disability. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
| Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) and up to approximately 4.5 years | The NEI-VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question to assess the patient's perception of vision-related functioning and vision-related quality of life. Items were coded to a 0 to 100 scale and were averaged to calculate domains. The composite score ranges from 0 (worst score) to 100 (best score), with higher scores indicating better vision-related functioning. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
| Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Up to approximately 4.5 years | The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. It included item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE like Anxious, Blurred Vision, Chills, Concentration, Constipation, Cough, Decreased Appetite, Discouraged, Dizziness, Fatigue, Heart Palpitations, Insomnia, Memory, Mouth/Throat Sores, Nausea, Nosebleed, Numbness & Tingling, Pain, Ringing In Ears, Shortness Of Breath, Vomiting and Watery Eyes. Number of participants with symptomatic AEs measured by PRO-CTCAEs are presented. |
| Number of Participants With AEs of Special Interest (AESI) | Up to approximately 4.5 years | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with AESI for belantamab mafodotin (corneal events, thrombocytopenia and infusion related reactions) are presented. |
| Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Baseline (Day 1) and up to approximately 4.5 years | BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
| Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Baseline (Day 1) and up to approximately 4.5 years | BCVA score was assessed individually for better seeing eye and worse seeing eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change post baseline categories are presented for better seeing eye and worse seeing eye. BCVA test scores by Snellen results were categorized as improved BCVA, \<= 2 lines decline in visual acuity from baseline, \>= 3 lines decline in visual acuity from baseline. Number of lines change from baseline was defined as the following: Improved BCVA equates to a negative change in logMAR from baseline BCVA. \<= 2 lines decline in visual acuity equates to logMAR change from baseline ≤0.37. \>= 3 lines decline in visual acuity equates to logMAR change from baseline ≥0.38. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
| Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Baseline (Day 1) and up to approximately 4.5 years | Number of participants with a Decline in BCVA to 'Light Perception (LP)' or 'No Light Perception (NLP)' due to a Corneal Event Anytime Post-Baseline are presented. BCVA score was assessed individually for each eye (Left and Right). Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Number of participants analyzed were who have any post-baseline BCVA score, where the Visual Acuity is due to corneal findings. |
| Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Baseline (Day 1) and up to approximately 4.5 years | Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Corneal epithelium findings like active edema, active opacity, corneal neovascularization (CN), corneal ulcer, epithelial microcystic edema (EME) and subepithelial haze were performed using a slit lamp. Number of participants with shift in corneal epithelium findings from no (Baseline) to yes (worst post-Baseline) are presented. |
| Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Baseline (Day 1) and up to approximately 4.5 years | Participants with worse grade punctate keratopathy findings post baseline at any ocular exam by right eye, left eye and worse eye are presented as none, mild, moderate and severe. Worse eye indicates the eye with the worst visual acuity. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT]) | The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value. |
| Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT]) | The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
| AUC (0-72h) for Bortezomib, Treatment B | Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose | Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 28 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 29; pre-dose Cycle 2 Day 28 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups. |
| Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and Day 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 21 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 11; Cycle 1 Day 22; Pre-Dose and Post-Dose on Week 5 Day 7 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008h) was derived only for Belantamab mafodotin 1.9 mg/kg STRETCH + Bor/Dex, Belantamab mafodotin 2.5 mg/kg StepDown STRETCH + Bor/Dex and Belantamab mafodotin 2.5 mg/kg STRETCH + Bor/Dex cohorts. |
| Tmax for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Tlast for Belantamab Mafodotin ADC, Treatment B | Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 5 Day 1 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups. |
| Ctrough for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| C-EOI for Belantamab Mafodotin ADC, Treatment B | Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 10 Day 8, Week 13 Day 1, Week 13 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
| Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8 | Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. |
Countries
Australia, Canada, Spain, United Kingdom, United States
Participant flow
Pre-assignment details
The study consisted of two phases - Main Study Phase (Day 1 to Month 53) and Post Analysis Continued Treatment (PACT) Phase (From Month 53 up to Month 65, which marks the completion of the PACT Phase for all participants). In PACT phase those participants still benefiting from drug continued to receive study drug until discontinued or withdrawn from study.
Participants by arm
| Arm | Count |
|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle. | 12 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle. | 4 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle. | 13 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle. | 16 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 12 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 12 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 12 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 12 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 13 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 18 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 12 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles. | 16 |
| Total | 152 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 | FG019 | FG020 | FG021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main Study Phase | Death | 3 | 2 | 6 | 8 | 4 | 2 | 4 | 5 | 5 | 8 | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Did not receive study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Investigator Site Closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Ongoing | 3 | 1 | 2 | 4 | 2 | 4 | 4 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Main Study Phase | Withdrawal by Subject | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PACT Phase | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex | Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 18 to <65 years | 3 Participants | 4 Participants | 4 Participants | 6 Participants | 4 Participants | 3 Participants | 4 Participants | 4 Participants | 5 Participants | 6 Participants | 6 Participants | 9 Participants | 58 Participants |
| Age, Customized 65 to <75 years | 1 Participants | 8 Participants | 8 Participants | 3 Participants | 5 Participants | 8 Participants | 7 Participants | 4 Participants | 5 Participants | 8 Participants | 5 Participants | 5 Participants | 67 Participants |
| Age, Customized >=75 years | 0 Participants | 1 Participants | 4 Participants | 3 Participants | 3 Participants | 1 Participants | 1 Participants | 4 Participants | 3 Participants | 4 Participants | 1 Participants | 2 Participants | 27 Participants |
| Race/Ethnicity, Customized African American/African Heritage | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants | 0 Participants | 4 Participants | 0 Participants | 1 Participants | 10 Participants |
| Race/Ethnicity, Customized Asian - Central/South Asian Heritage | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Asian - East Asian Heritage | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian - South East Asian Heritage | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized White - Arabic/North African Heritage | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White - White/Caucasian/European Heritage | 4 Participants | 13 Participants | 13 Participants | 11 Participants | 11 Participants | 11 Participants | 10 Participants | 7 Participants | 11 Participants | 12 Participants | 11 Participants | 15 Participants | 129 Participants |
| Sex: Female, Male Female | 0 Participants | 5 Participants | 3 Participants | 5 Participants | 2 Participants | 3 Participants | 5 Participants | 7 Participants | 2 Participants | 7 Participants | 4 Participants | 5 Participants | 48 Participants |
| Sex: Female, Male Male | 4 Participants | 8 Participants | 13 Participants | 7 Participants | 10 Participants | 9 Participants | 7 Participants | 5 Participants | 11 Participants | 11 Participants | 8 Participants | 11 Participants | 104 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk | EG020 affected / at risk | EG021 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 12 | 2 / 4 | 6 / 13 | 8 / 16 | 4 / 12 | 2 / 12 | 4 / 12 | 5 / 12 | 5 / 13 | 8 / 18 | 6 / 12 | 4 / 16 | 0 / 3 | 0 / 1 | 0 / 2 | 0 / 4 | 0 / 2 | 0 / 4 | 0 / 4 | 0 / 2 | 0 / 2 | 0 / 1 |
| other Total, other adverse events | 12 / 12 | 4 / 4 | 13 / 13 | 16 / 16 | 12 / 12 | 12 / 12 | 12 / 12 | 12 / 12 | 13 / 13 | 18 / 18 | 12 / 12 | 16 / 16 | 0 / 3 | 0 / 1 | 0 / 2 | 0 / 4 | 0 / 2 | 0 / 4 | 0 / 4 | 0 / 2 | 0 / 2 | 0 / 1 |
| serious Total, serious adverse events | 6 / 12 | 2 / 4 | 6 / 13 | 10 / 16 | 8 / 12 | 8 / 12 | 6 / 12 | 6 / 12 | 7 / 13 | 13 / 18 | 6 / 12 | 9 / 16 | 1 / 3 | 0 / 1 | 0 / 2 | 2 / 4 | 1 / 2 | 1 / 4 | 1 / 4 | 0 / 2 | 0 / 2 | 0 / 1 |
Outcome results
Primary
Change From Baseline in Urine Potential of Hydrogen (pH)
Urine samples were collected to analyze urine pH levels. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.9 Potential of Hydrogen (pH) | Standard Deviation 0.46 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.1 Potential of Hydrogen (pH) | Standard Deviation 1.08 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.8 Potential of Hydrogen (pH) | Standard Deviation 0.65 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | -0.2 Potential of Hydrogen (pH) | Standard Deviation 0.76 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 6.0 Potential of Hydrogen (pH) | Standard Deviation 0.9 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.4 Potential of Hydrogen (pH) | Standard Deviation 1.38 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.8 Potential of Hydrogen (pH) | Standard Deviation 0.69 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.2 Potential of Hydrogen (pH) | Standard Deviation 0.29 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 6.1 Potential of Hydrogen (pH) | Standard Deviation 0.68 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | -0.3 Potential of Hydrogen (pH) | Standard Deviation 0.61 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.6 Potential of Hydrogen (pH) | Standard Deviation 0.42 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.8 Potential of Hydrogen (pH) | Standard Deviation 0.62 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | -0.5 Potential of Hydrogen (pH) | Standard Deviation 0.5 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 6.4 Potential of Hydrogen (pH) | Standard Deviation 0.87 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.2 Potential of Hydrogen (pH) | Standard Deviation 0.66 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.6 Potential of Hydrogen (pH) | Standard Deviation 0.48 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.9 Potential of Hydrogen (pH) | Standard Deviation 0.82 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.4 Potential of Hydrogen (pH) | Standard Deviation 1.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 6.1 Potential of Hydrogen (pH) | Standard Deviation 0.82 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.2 Potential of Hydrogen (pH) | Standard Deviation 0.8 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.9 Potential of Hydrogen (pH) | Standard Deviation 1.18 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.4 Potential of Hydrogen (pH) | Standard Deviation 0.55 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) | 5.7 Potential of Hydrogen (pH) | Standard Deviation 0.7 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Potential of Hydrogen (pH) | Change from baseline (up to approx. 4.5 years) | 0.2 Potential of Hydrogen (pH) | Standard Deviation 1.05 |
Primary
Change From Baseline in Urine Specific Gravity
Urine samples were collected to analyze urine specific gravity using dipstick method. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0217 Ratio | Standard Deviation 0.00687 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0003 Ratio | Standard Deviation 0.00058 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0253 Ratio | Standard Deviation 0.0066 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | -0.0090 Ratio | Standard Deviation 0.01217 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0169 Ratio | Standard Deviation 0.00946 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | -0.0013 Ratio | Standard Deviation 0.01072 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0175 Ratio | Standard Deviation 0.00682 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0023 Ratio | Standard Deviation 0.00643 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0075 Ratio | Standard Deviation 0.00354 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0217 Ratio | Standard Deviation 0.00931 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0175 Ratio | Standard Deviation 0.00544 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | -0.0020 Ratio | Standard Deviation 0.00671 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0050 Ratio | Standard Deviation 0.00707 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0133 Ratio | Standard Deviation 0.00661 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0167 Ratio | Standard Deviation 0.00736 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0029 Ratio | Standard Deviation 0.01029 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0193 Ratio | Standard Deviation 0.00612 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | -0.0010 Ratio | Standard Deviation 0.00529 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0152 Ratio | Standard Deviation 0.00817 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0005 Ratio | Standard Deviation 0.00782 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | -0.0026 Ratio | Standard Deviation 0.00792 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0174 Ratio | Standard Deviation 0.00713 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Change from baseline (up to approx. 4.5 years) | 0.0067 Ratio | Standard Deviation 0.0083 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Urine Specific Gravity | Baseline (Day 1) | 1.0139 Ratio | Standard Deviation 0.00627 |
Primary
Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Data was not collected where number of participants analyzed is 0. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | -4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | 5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | 9.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | 9.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 72.3 Millimeters of mercury (mmHg) | Standard Deviation 7.67 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 127.8 Millimeters of mercury (mmHg) | Standard Deviation 18.62 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 173 DAY 1, Predose | -14.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 137.5 Millimeters of mercury (mmHg) | Standard Deviation 7.05 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 86.0 Millimeters of mercury (mmHg) | Standard Deviation 12.49 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 173 DAY 1, Predose | -7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 173 DAY 1, 0.25hour Post-Dose | -7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 173 DAY 1, 1hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 173 DAY 1, 1hour Post-Dose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 173 DAY 1, 0.25hour Post-Dose | -10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | 2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 153 DAY 8, 0.25hour Post-Dose | 13.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 136.1 Millimeters of mercury (mmHg) | Standard Deviation 26.03 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 79.5 Millimeters of mercury (mmHg) | Standard Deviation 9.36 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | 2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 153 DAY 8, Predose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 153 DAY 8, 1hour Post-Dose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 153 DAY 8, 1hour Post-Dose | 7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 153 DAY 8, 0.25hour Post-Dose | 10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 153 DAY 8, Predose | 5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 221 DAY 1, 0.25hour Post-Dose | -10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 125.3 Millimeters of mercury (mmHg) | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | -4.7 Millimeters of mercury (mmHg) | Standard Deviation 16.01 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 1hour Post-Dose | 5.0 Millimeters of mercury (mmHg) | Standard Deviation 19.8 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 71.4 Millimeters of mercury (mmHg) | Standard Deviation 12.04 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 221 DAY 1, 1hour Post-Dose | 32.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | -1.7 Millimeters of mercury (mmHg) | Standard Deviation 2.08 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 221 DAY 1, 0.25hour Post-Dose | 15.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 6.24 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 221 DAY 1, Predose | 18.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 5.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 1.3 Millimeters of mercury (mmHg) | Standard Deviation 15.89 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, Predose | -2.0 Millimeters of mercury (mmHg) | Standard Deviation 2.83 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 0.25hour Post-Dose | 1.0 Millimeters of mercury (mmHg) | Standard Deviation 7.07 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 1hour Post-Dose | 4.5 Millimeters of mercury (mmHg) | Standard Deviation 3.54 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, Predose | -9.0 Millimeters of mercury (mmHg) | Standard Deviation 1.41 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | 7.3 Millimeters of mercury (mmHg) | Standard Deviation 16.56 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | Standard Deviation 9.9 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 221 DAY 1, Predose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 221 DAY 1, 1hour Post-Dose | 2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | 10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 73.6 Millimeters of mercury (mmHg) | Standard Deviation 17.15 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 136.4 Millimeters of mercury (mmHg) | Standard Deviation 18.99 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -8.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | 12.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | 11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 1hour Post-Dose | 10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, Predose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 0.25hour Post-Dose | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | -6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | 5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 0.25hour Post-Dose | -15.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 1hour Post-Dose | 21.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, Predose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 129.7 Millimeters of mercury (mmHg) | Standard Deviation 15.13 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 75.1 Millimeters of mercury (mmHg) | Standard Deviation 9.08 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 132.8 Millimeters of mercury (mmHg) | Standard Deviation 17.88 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 0.25hour Post-Dose | -30.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 0.25hour Post-Dose | -21.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 1hour Post-Dose | -21.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 78.4 Millimeters of mercury (mmHg) | Standard Deviation 11.13 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, Predose | -24.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, Predose | -28.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 1hour Post-Dose | -35.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, Predose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 1hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 0.25hour Post-Dose | 10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, Predose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 135.4 Millimeters of mercury (mmHg) | Standard Deviation 16.68 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 0.25hour Post-Dose | 17.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 1hour Post-Dose | 16.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 76.1 Millimeters of mercury (mmHg) | Standard Deviation 7.14 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, Predose | -4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 0.25hour Post-Dose | -4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | 19.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 0.25hour Post-Dose | -3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 1hour Post-Dose | -4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | -1.0 Millimeters of mercury (mmHg) | Standard Deviation 5.66 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, Predose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | -7.5 Millimeters of mercury (mmHg) | Standard Deviation 0.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 0.25hour Post-Dose | 1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | -1.5 Millimeters of mercury (mmHg) | Standard Deviation 4.95 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 72.2 Millimeters of mercury (mmHg) | Standard Deviation 8.52 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 1hour Post-Dose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, Predose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 0.25hour Post-Dose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 1hour Post-Dose | 14.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | -4.5 Millimeters of mercury (mmHg) | Standard Deviation 0.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | 12.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 1.5 Millimeters of mercury (mmHg) | Standard Deviation 7.78 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | 5.5 Millimeters of mercury (mmHg) | Standard Deviation 2.12 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, Predose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 1hour Post-Dose | 8.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 8, 1hour Post-Dose | 17.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, Predose | 11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 8, 0.25hour Post-Dose | 11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, 0.25hour Post-Dose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, 1hour Post-Dose | 7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 8, Predose | 11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 8, 0.25hour Post-Dose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 8, 1hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 122.3 Millimeters of mercury (mmHg) | Standard Deviation 13.94 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 8, Predose | 10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, 1hour Post-Dose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | 8.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | 19.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, 0.25hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, Predose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | 8.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, Predose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 1hour Post-Dose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, Predose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 0.25hour Post-Dose | 12.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 1hour Post-Dose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, Predose | -16.5 Millimeters of mercury (mmHg) | Standard Deviation 26.16 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | 2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | 5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, Predose | -26.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 0.25hour Post-Dose | -15.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 91 DAY 1, 1hour Post-Dose | -16.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, Predose | -7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 0.25hour Post-Dose | 4.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 1hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 6.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | Standard Deviation 4.24 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 169 DAY 1, 1hour Post-Dose | -11.0 Millimeters of mercury (mmHg) | Standard Deviation 16.97 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 143.3 Millimeters of mercury (mmHg) | Standard Deviation 25.93 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | 16.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | 9.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, Predose | -22.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 0.25hour Post-Dose | -31.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 91 DAY 1, 1hour Post-Dose | -15.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, Predose | -38.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 0.25hour Post-Dose | -23.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 1hour Post-Dose | -32.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | -11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | 8.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, Predose | -16.5 Millimeters of mercury (mmHg) | Standard Deviation 28.99 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, 0.25hour Post-Dose | -9.5 Millimeters of mercury (mmHg) | Standard Deviation 7.78 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 169 DAY 1, 1hour Post-Dose | -6.5 Millimeters of mercury (mmHg) | Standard Deviation 9.19 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 74.9 Millimeters of mercury (mmHg) | Standard Deviation 8.77 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -36.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 1hour Post-Dose | 2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, 0.25hour Post-Dose | 3.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 94 DAY 1, Predose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 126.8 Millimeters of mercury (mmHg) | Standard Deviation 21.48 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | -10.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 72.9 Millimeters of mercury (mmHg) | Standard Deviation 11.85 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -11.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, Predose | 12.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | -41.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | -17.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 94 DAY 1, 1hour Post-Dose | -5.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, Predose | -14.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 1hour Post-Dose | -44.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -14.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 1hour Post-Dose | -31.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, 0.25hour Post-Dose | -23.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 109 DAY 1, Predose | -22.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, Predose | -16.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 0.25hour Post-Dose | -2.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 1hour Post-Dose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 133 DAY 1, 1hour Post-Dose | -1.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, 0.25hour Post-Dose | -7.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, WEEK 79 DAY 1, Predose | -21.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 79 DAY 1, Predose | -23.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | SBP, BASELINE (Day 1) | 138.5 Millimeters of mercury (mmHg) | Standard Deviation 21.29 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, BASELINE (Day 1) | 77.8 Millimeters of mercury (mmHg) | Standard Deviation 10.61 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 1hour Post-Dose | -14.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, 0.25hour Post-Dose | -18.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 133 DAY 1, Predose | -16.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 1hour Post-Dose | -27.0 Millimeters of mercury (mmHg) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | DBP, WEEK 109 DAY 1, 0.25hour Post-Dose | -21.0 Millimeters of mercury (mmHg) | — |
Primary
Change From Baseline in Vital Signs : Pulse Rate
Pulse rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 72.8 beats per minute | Standard Deviation 9.01 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | -19.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | -18.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | -4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 73.8 beats per minute | Standard Deviation 11.9 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 173 DAY 1, 0.25hour Post-Dose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 173 DAY 1, 1hour Post-Dose | -8.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 173 DAY 1, Predose | -7.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 153 DAY 8, 0.25hour Post-Dose | -10.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 153 DAY 8, 1hour Post-Dose | -9.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 76.0 beats per minute | Standard Deviation 17.1 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 153 DAY 8, Predose | -8.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | -25.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | -22.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | -24.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 72.8 beats per minute | Standard Deviation 14.65 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | 0.3 beats per minute | Standard Deviation 3.06 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 221 DAY 1, 1hour Post-Dose | 8.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | 8.3 beats per minute | Standard Deviation 5.13 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 221 DAY 1, 0.25hour Post-Dose | 2.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 221 DAY 1, Predose | -4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 1hour Post-Dose | 5.5 beats per minute | Standard Deviation 2.12 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 0.25hour Post-Dose | 4.5 beats per minute | Standard Deviation 0.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, Predose | 6.5 beats per minute | Standard Deviation 9.19 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | 1.3 beats per minute | Standard Deviation 5.69 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | -6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 73.7 beats per minute | Standard Deviation 13.05 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | -9.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | -18.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | -18.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | 6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, Predose | 1.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 0.25hour Post-Dose | -2.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 76.2 beats per minute | Standard Deviation 12.69 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | -6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 1hour Post-Dose | -6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 1hour Post-Dose | -4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 0.25hour Post-Dose | -4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, Predose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 75.5 beats per minute | Standard Deviation 11.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, Predose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 79.6 beats per minute | Standard Deviation 13.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 1hour Post-Dose | -11.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 0.25hour Post-Dose | -19.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, 0.25hour Post-Dose | -23.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 73.3 beats per minute | Standard Deviation 14.31 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | -14.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | 6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | 13.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, Predose | 24.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 0.25hour Post-Dose | 12.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 1hour Post-Dose | 11.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, Predose | -14.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 0.25hour Post-Dose | -22.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 1hour Post-Dose | -28.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | -6.0 beats per minute | Standard Deviation 8.49 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | 10.5 beats per minute | Standard Deviation 41.72 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | -8.0 beats per minute | Standard Deviation 11.31 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, Predose | -11.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 0.25hour Post-Dose | -12.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 1hour Post-Dose | -16.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, Predose | -15.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, 1hour Post-Dose | -20.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 8, Predose | -21.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 8, 0.25hour Post-Dose | -17.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 8, 1hour Post-Dose | -20.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 1hour Post-Dose | 11.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | 9.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | -12.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | -12.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 0.25hour Post-Dose | -9.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, Predose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | -2.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 91 DAY 1, 1hour Post-Dose | -19.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, Predose | -21.0 beats per minute | Standard Deviation 5.66 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | -2.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, 0.25hour Post-Dose | -19.0 beats per minute | Standard Deviation 2.83 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 0.25hour Post-Dose | 16.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 169 DAY 1, 1hour Post-Dose | -21.0 beats per minute | Standard Deviation 1.41 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | -16.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, Predose | 21.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 74.1 beats per minute | Standard Deviation 10.76 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 0.25hour Post-Dose | 12.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, 1hour Post-Dose | 14.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 94 DAY 1, Predose | 13.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | 4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | 2.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 81.0 beats per minute | Standard Deviation 10.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | 1.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 0.25hour Post-Dose | -8.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | BASELINE (Day 1) | 75.3 beats per minute | Standard Deviation 10.82 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, 1hour Post-Dose | 0.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, Predose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 1hour Post-Dose | -6.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 0.25hour Post-Dose | -5.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, Predose | 4.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 133 DAY 1, 1hour Post-Dose | -17.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 79 DAY 1, 0.25hour Post-Dose | -9.0 beats per minute | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Pulse Rate | WEEK 109 DAY 1, Predose | -9.0 beats per minute | — |
Primary
Change From Baseline in Vital Signs : Temperature
Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.61 Degree Celsius (C) | Standard Deviation 0.417 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | -1.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | -0.90 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | -1.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 173 DAY 1, 1hour Post-Dose | -0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 173 DAY 1, Predose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 173 DAY 1, 0.25hour Post-Dose | -0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.70 Degree Celsius (C) | Standard Deviation 0.346 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 153 DAY 8, 1hour Post-Dose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | -0.80 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | -0.80 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.46 Degree Celsius (C) | Standard Deviation 0.307 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 153 DAY 8, 0.25hour Post-Dose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 153 DAY 8, Predose | 0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | -0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 221 DAY 1, 1hour Post-Dose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | 0.20 Degree Celsius (C) | Standard Deviation 0.173 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | 0.07 Degree Celsius (C) | Standard Deviation 0.153 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.43 Degree Celsius (C) | Standard Deviation 0.334 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 1hour Post-Dose | 0.45 Degree Celsius (C) | Standard Deviation 0.071 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 0.25hour Post-Dose | 0.25 Degree Celsius (C) | Standard Deviation 0.071 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, Predose | 0.60 Degree Celsius (C) | Standard Deviation 0.283 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | 0.10 Degree Celsius (C) | Standard Deviation 0.173 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 221 DAY 1, 0.25hour Post-Dose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 221 DAY 1, Predose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.46 Degree Celsius (C) | Standard Deviation 0.348 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, Predose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.44 Degree Celsius (C) | Standard Deviation 0.291 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 1hour Post-Dose | 0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 0.25hour Post-Dose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.52 Degree Celsius (C) | Standard Deviation 0.432 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 0.25hour Post-Dose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, Predose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 1hour Post-Dose | -0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 1hour Post-Dose | -0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.68 Degree Celsius (C) | Standard Deviation 0.305 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, Predose | -0.60 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 0.25hour Post-Dose | -0.80 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 0.25hour Post-Dose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.53 Degree Celsius (C) | Standard Deviation 0.338 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | 0.70 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | 0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, Predose | 0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 0.25hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 1hour Post-Dose | 0.50 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, Predose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 0.25hour Post-Dose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 1hour Post-Dose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | 0.20 Degree Celsius (C) | Standard Deviation 0.283 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | 0.15 Degree Celsius (C) | Standard Deviation 0.071 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | 0.15 Degree Celsius (C) | Standard Deviation 0.071 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, Predose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 1hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, Predose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, 0.25hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, 1hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 8, Predose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 8, 0.25hour Post-Dose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 8, 1hour Post-Dose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, Predose | -0.70 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | 0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 1hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, Predose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | -0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, Predose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 1hour Post-Dose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 0.25hour Post-Dose | 0.10 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 91 DAY 1, 0.25hour Post-Dose | 0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, 1hour Post-Dose | -0.05 Degree Celsius (C) | Standard Deviation 0.071 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | -0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.48 Degree Celsius (C) | Standard Deviation 0.571 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 169 DAY 1, 0.25hour Post-Dose | 0.05 Degree Celsius (C) | Standard Deviation 0.636 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 148 DAY 8, 1hour Post-Dose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.51 Degree Celsius (C) | Standard Deviation 0.581 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | 1.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 148 DAY 8, Predose | 0.00 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 148 DAY 8, 0.25hour Post-Dose | -0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | 1.60 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | 1.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 1hour Post-Dose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, 0.25hour Post-Dose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 94 DAY 1, Predose | 0.30 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 0.25hour Post-Dose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, 1hour Post-Dose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 1hour Post-Dose | 0.20 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, 0.25hour Post-Dose | 0.70 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 109 DAY 1, Predose | 0.40 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 133 DAY 1, Predose | 1.00 Degree Celsius (C) | — |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, Predose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 0.25hour Post-Dose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | BASELINE (Day 1) | 36.58 Degree Celsius (C) | Standard Deviation 0.397 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Vital Signs : Temperature | WEEK 79 DAY 1, 1hour Post-Dose | 0.00 Degree Celsius (C) | Standard Deviation 0 |
Primary
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
Time frame: Up to approximately 4.5 years
Population: All treated population included all participants who received at least one dose of study treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 16 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 18 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAE | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any AE | 16 Participants |
Primary
Number of Participants With DLTs, Treatment B
DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment).
Time frame: Up to 21 days
Population: DLT-evaluable population included participants who received at least 1 full dose of belantamab mafodotin and at least 75% of planned doses of Bor/Dex by the end of Cycle 1 (Day 21). As pre-specified in protocol, only specified treatment arms were planned to be analyzed for DLTs.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With DLTs, Treatment B | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With DLTs, Treatment B | 0 Participants |
Primary
Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A
DLT is an adverse event (AE) that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28 day DLT period and meets at least one of the DLT criteria: Grade 3 or greater febrile neutropenia lasting \>48 hours (h) despite adequate treatment; Grade 4 thrombocytopenia \<25,000/mm\^3 accompanied by significant bleeding; any Grade 3 or greater non-hematologic laboratory value (if laboratory abnormality persist \>48 h despite supportive treatment or abnormality leading to hospitalisation); non-hematologic toxicity which does not resolve with appropriate supportive treatment within 48 h, Grade 4 corneal adverse events; and other organ specific toxicities (liver toxicity that causes discontinuation of treatment).
Time frame: Up to 28 days
Population: DLT-evaluable population included participants who received at least 1 full dose of belantamab mafodotin and at least 75% of planned doses of Len/Dex by the end of Cycle 1 (Day 28). As pre-specified in protocol, only specified treatment arms were planned to be analyzed for DLTs.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A | 0 Participants |
Primary
Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF)
12-lead electrocardiogram (ECGs) were obtained using an automated ECG machine that automatically calculated the QTcF intervals. QTc values are categorized into the clinical concern ranges which are specific to changes in QTc: 31-60 milliseconds (msec), and \>60 msec, and \>530msec. An increase is defined relative to Baseline. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Data of number of participants with worst-case increase post baseline is presented.
Time frame: Up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >530 msec | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of 31-60 msec | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF) | Increase of >60 msec | 0 Participants |
Primary
Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of following clinical chemistry parameters: Direct Bilirubin (DB), Calcium, Chloride, Carbon Dioxide (CO2), lactate dehydrogenase (LDH) and Protein. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed. Participants are counted twice if the participant has values that changed Decreased to Low and Increased to High, so the sum of the percentages may not add to 100% for each category.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 14 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Decrease to Low | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Change to Normal or No Change | 14 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | DB, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Protein, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Increase to High | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | LDH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Calcium, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | Chloride, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters | CO2, Increase to High | 3 Participants |
Primary
Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes, erythrocytes and reticulocyte. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by CTCAE version 4.03. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values from baseline have been presented. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed. Participants are counted twice if the participant has values that changed Decreased to Low and Increased to High, so the sum of the percentages may not add to 100% for each category.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 14 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 14 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Change to Normal or No Change | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Decrease to Low | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Increase to High | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Increase to High | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Basophils, Change to Normal or No Change | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Decrease to Low | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Increase to High | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Decrease to Low | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Reticulocytes, Change to Normal or No Change | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Change to Normal or No Change | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCH, Increase to High | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Change to Normal or No Change | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCV, Increase to High | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Erythrocytes, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | MCHC, Decrease to Low | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Decrease to Low | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Monocytes, Change to Normal or No Change | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Eosinophils, Increase to High | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post-baseline in Hematology Parameters | Hematocrit, Decrease to Low | 7 Participants |
Primary
Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein
Urine samples were collected to analyze presence of occult blood and protein in urine by dipstick method. Data for worst-case post baseline urinalysis results is presented. Result for urinalysis parameters were recorded as no change/decreased and increase to trace, 1+, 2+, 3+, \>3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 1+ | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, No Change/Decreased | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, No Change/Decreased | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 2+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to 3+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 2+ | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to 1+ | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Occult Blood, Increase to TRACE | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to >3+ | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein | Protein, Increase to TRACE | 1 Participants |
Primary
Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of following clinical chemistry parameters: Hyperglycemia, Hypoglycemia, Albumin, Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase, (AST), Bilirubin, Creatine Kinase (CK), Creatinine, Gamma Glutamyl Transferase (GGT), Hyperkalemia, Hypokalemia, Hypermagnesemia, Hypomagnesemia, Phosphate, Hypernatremia, Hyponatremia, Urate, Hypercalcemia and Hypocalcemia. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 14 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Phosphate, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | CK, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Albumin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Alkaline Phosphatase, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | GGT, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypomagnesemia, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Urate, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Bilirubin, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypermagnesemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia, Increase to Grade 4 | 0 Participants |
Primary
Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of following hematology parameters: Hemoglobin (hemoglobin increased and anemia), Lymphocytes (lymphocyte count increased and lymphocyte count decreased), Neutrophils, Platelets and Leukocytes (leukocytosis and white blood cells decreased). The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. Grade (G) 1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Any worst-case post baseline increases in grade along with any increase to a maximum G3 and a maximum G4 are presented.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All treated population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 18 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Any Grade Increase | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 3 | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 4 | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Any Grade Increase | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count decreased, Increase to Grade 4 | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Increase to Grade 3 | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 3 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia, Any Grade Increase | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Increase to Grade 3 | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte count increased, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelets, Any Grade Increase | 16 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Increase to Grade 4 | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin increased, Any Grade Increase | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophils, Any Grade Increase | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White blood cell decreased, Any Grade Increase | 13 Participants |
Primary
Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM)
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasmacytomas in the bone marrow; sCR: stringent complete response, CR as above plus normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR \>= 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 h. Confidence intervals were based on the exact method.
Time frame: Up to approximately 4.5 years
Population: All treated population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 58 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 75 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 69 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 69 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 50 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 83 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 92 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 75 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 62 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 78 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 50 Percentage of Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM) | 69 Percentage of Participants |
Secondary
Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A | 3848.41 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 24.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A | 4802.83 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 34.51 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A | 4365.82 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 10.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Area Under the Concentration Time Curve (AUC) From Time 0 to 504 Hours (0-504h) for Belantamab Mafodotin ADC, Treatment A | 4127.66 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 17.98 |
Secondary
AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008h) was derived only for Belantamab mafodotin 1.9 mg/kg STRETCH + Bor/Dex, Belantamab mafodotin 2.5 mg/kg StepDown STRETCH + Bor/Dex and Belantamab mafodotin 2.5 mg/kg STRETCH + Bor/Dex cohorts.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 11; Cycle 1 Day 22; Pre-Dose and Post-Dose on Week 5 Day 7
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed. As per protocol, blood sampling for PK was performed for only specified treatment arms for this OM and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B | 7084.63 h*ug/mL | Geometric Coefficient of Variation 24.82 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B | 7396.49 h*ug/mL | Geometric Coefficient of Variation 25.94 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin ADC, Treatment B | 6487.41 h*ug/mL | Geometric Coefficient of Variation 26.24 |
Secondary
AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008) was derived only for Belantamab mafodotin 1.9mg/kg + Len/Dex STRETCH cohort.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 29; Pre-Dose and Post-Dose on Week 5 Day 7
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment A | 8143.85 h*ug/mL | Geometric Coefficient of Variation 30.12 |
Secondary
AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1008h) was derived only for Belantamab mafodotin 1.9 mg/kg STRETCH + Bor/Dex, Belantamab mafodotin 2.5 mg/kg StepDown STRETCH + Bor/Dex and Belantamab mafodotin 2.5 mg/kg STRETCH + Bor/Dex cohorts.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 11; Cycle 1 Day 22; Pre-Dose and Post-Dose on Week 5 Day 7
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B | 11656.56 h*ug/mL | Geometric Coefficient of Variation 25.11 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B | 11328.37 h*ug/mL | Geometric Coefficient of Variation 40.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-1008h) for Belantamab Mafodotin (Total Antibody), Treatment B | 11178.97 h*ug/mL | Geometric Coefficient of Variation 49.1 |
Secondary
AUC(0-1344h) for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC(0-1344) was derived only for Belantamab mafodotin 1.9mg/kg + Len/Dex STRETCH cohort.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 29; Pre-Dose and Post-Dose on Week 7 Day 7
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC(0-1344h) for Belantamab Mafodotin (Total Antibody), Treatment A | 8633.05 h*ug/mL | Geometric Coefficient of Variation 30.26 |
Secondary
AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1, and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 106.21 h*ug/mL | Geometric Coefficient of Variation 55.99 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | NA h*ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 43.15 h*ug/mL | Geometric Coefficient of Variation 26.42 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 8 | 51.31 h*ug/mL | Geometric Coefficient of Variation 30.45 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 113.58 h*ug/mL | Geometric Coefficient of Variation 49.61 |
Secondary
AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1, Cycle 1 Day 4; and Cycle 1 Day 7
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 89.05 h*ug/mL | Geometric Coefficient of Variation 41.52 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 52.82 h*ug/mL | Geometric Coefficient of Variation 96.74 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | AUC(0-168h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 81.17 h*ug/mL | Geometric Coefficient of Variation 31.46 |
Secondary
AUC(0-24h) for Lenalidomide (10 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 10 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC(0-24h) for Lenalidomide (10 mg), Treatment A | 1660.82 h*ug/mL | Geometric Coefficient of Variation 22.4 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC(0-24h) for Lenalidomide (10 mg), Treatment A | NA h*ug/mL | — |
Secondary
AUC(0-24h) for Lenalidomide (25 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 25 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC(0-24h) for Lenalidomide (25 mg), Treatment A | 2247.36 h*ug/mL | Geometric Coefficient of Variation 65.76 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC(0-24h) for Lenalidomide (25 mg), Treatment A | 1577.62 h*ug/mL | Geometric Coefficient of Variation 21.66 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC(0-24h) for Lenalidomide (25 mg), Treatment A | 2117.26 h*ug/mL | Geometric Coefficient of Variation 38.21 |
Secondary
AUC (0-336h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC (0-336h) was derived only for the Belantamab mafodotin 2.5mg/kg + Len/Dex SPLIT cohort.
Time frame: Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 14
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-336h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | 93.84 h*ug/mL | Geometric Coefficient of Variation 29.16 |
Secondary
AUC (0-4h) for Lenalidomide (10 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2 and 4 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 10 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-4h) for Lenalidomide (10 mg), Treatment A | 486.46 h*ug/mL | Geometric Coefficient of Variation 41.84 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-4h) for Lenalidomide (10 mg), Treatment A | NA h*ug/mL | — |
Secondary
AUC (0-4h) for Lenalidomide (25 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2 and 4 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 25 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-4h) for Lenalidomide (25 mg), Treatment A | 812.22 h*ug/mL | Geometric Coefficient of Variation 105.88 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-4h) for Lenalidomide (25 mg), Treatment A | 870.92 h*ug/mL | Geometric Coefficient of Variation 19.36 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-4h) for Lenalidomide (25 mg), Treatment A | 620.10 h*ug/mL | Geometric Coefficient of Variation 44.84 |
Secondary
AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 21
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 6129.71 h*ug/mL | Geometric Coefficient of Variation 23.83 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 4451.74 h*ug/mL | Geometric Coefficient of Variation 23.33 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 6073.99 h*ug/mL | Geometric Coefficient of Variation 37.06 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 5395.98 h*ug/mL | Geometric Coefficient of Variation 20.49 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 4341.73 h*ug/mL | Geometric Coefficient of Variation 22.36 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 5013.84 h*ug/mL | Geometric Coefficient of Variation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 5702.03 h*ug/mL | Geometric Coefficient of Variation 26.3 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin ADC, Treatment B | 6230.16 h*ug/mL | Geometric Coefficient of Variation 35.02 |
Secondary
AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A | 6648.19 h*ug/mL | Geometric Coefficient of Variation 35.67 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A | 6607.45 h*ug/mL | Geometric Coefficient of Variation 35.62 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A | 6909.91 h*ug/mL | Geometric Coefficient of Variation 24.7 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment A | 7277.25 h*ug/mL | Geometric Coefficient of Variation 28 |
Secondary
AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 21
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 7310.17 h*ug/mL | Geometric Coefficient of Variation 37.27 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 6094.55 h*ug/mL | Geometric Coefficient of Variation 33.37 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 8386.87 h*ug/mL | Geometric Coefficient of Variation 25.44 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 9891.43 h*ug/mL | Geometric Coefficient of Variation 29.93 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 8283.76 h*ug/mL | Geometric Coefficient of Variation 32.51 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 8207.69 h*ug/mL | Geometric Coefficient of Variation 41.72 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 9812.19 h*ug/mL | Geometric Coefficient of Variation 27.13 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-504h) for Belantamab Mafodotin (Total Antibody), Treatment B | 12581.08 h*ug/mL | Geometric Coefficient of Variation 28.13 |
Secondary
AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 28
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A | 4093.12 h*ug/mL | Geometric Coefficient of Variation 24.45 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A | 5114.28 h*ug/mL | Geometric Coefficient of Variation 34.72 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A | 4699.00 h*ug/mL | Geometric Coefficient of Variation 11.1 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin ADC, Treatment A | 4432.11 h*ug/mL | Geometric Coefficient of Variation 17.65 |
Secondary
AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 28
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A | 7408.65 h*ug/mL | Geometric Coefficient of Variation 36.03 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A | 7249.58 h*ug/mL | Geometric Coefficient of Variation 39 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A | 7828.12 h*ug/mL | Geometric Coefficient of Variation 27.15 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | AUC (0-672h) for Belantamab Mafodotin (Total Antibody), Treatment A | 8146.00 h*ug/mL | Geometric Coefficient of Variation 28.29 |
Secondary
AUC (0-72h) for Bortezomib, Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose
Population: Pharmacokinetic (PK) population. Only those participants who received Bortezomib with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-72h) for Bortezomib, Treatment B | Subcutaneous | 95.10 h*ug/mL | Geometric Coefficient of Variation 21.71 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-72h) for Bortezomib, Treatment B | Intravenous | NA h*ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-72h) for Bortezomib, Treatment B | Subcutaneous | 73.03 h*ug/mL | Geometric Coefficient of Variation 30.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-72h) for Bortezomib, Treatment B | Intravenous | NA h*ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-72h) for Bortezomib, Treatment B | Subcutaneous | 73.06 h*ug/mL | Geometric Coefficient of Variation 21.57 |
Secondary
AUC (0-t) for Bortezomib, Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose
Population: Pharmacokinetic (PK) population. Only those participants who received Bortezomib with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | AUC (0-t) for Bortezomib, Treatment B | Subcutaneous | 89.48 h*ug/mL | Geometric Coefficient of Variation 25.5 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-t) for Bortezomib, Treatment B | Intravenous | NA h*ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | AUC (0-t) for Bortezomib, Treatment B | Subcutaneous | 69.51 h*ug/mL | Geometric Coefficient of Variation 31.87 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-t) for Bortezomib, Treatment B | Intravenous | NA h*ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | AUC (0-t) for Bortezomib, Treatment B | Subcutaneous | 71.70 h*ug/mL | Geometric Coefficient of Variation 26.79 |
Secondary
C-EOI for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 10 Day 8, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 44.75 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 48.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 44.05 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 44.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 46.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | 43.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 36.45 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | 38.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 52.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 45.25 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 42.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 22.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 22.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 27.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 26.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 31.70 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 45.80 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 44.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 11 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 32.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 30.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 27.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 26.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 38.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 54.85 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | 46.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 51.20 ug/mL |
Secondary
C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 7 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.43 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 9 DAY 1 | 0.29 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.187 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 5 DAY 1 | 0.16 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 7 DAY 8 | 0.23 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.19 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 8 | 0.29 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 5 DAY 1 | 0.13 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 9 DAY 1 | 0.13 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 9 DAY 8 | 0.24 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 13 DAY 8 | 0.243 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 13 DAY 1 | 0.68 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 5 DAY 1 | 0.28 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.29 ug/mL |
Secondary
C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 10 Day 8, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.29 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.21 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 4 DAY 1 | 0.19 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.21 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.17 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 1 | 0.236 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | 0.222 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.28 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.31 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.32 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.27 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.19 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 8 | 0.27 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 4 DAY 1 | 0.21 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 4 DAY 1 | 0.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.29 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.24 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 11 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 8 | 0.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.27 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 4 DAY 1 | 0.26 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 0.39 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 7 DAY 1 | 0.36 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 4 DAY 1 | 0.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | WEEK 13 DAY 1 | 0.24 ug/mL |
Secondary
C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 5 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 42.70 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | 41.80 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 42.15 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 36.90 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 27.25 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 8 | 35.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 27.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 8 | 36.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | 31.25 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 8 | 39.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | 50.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 45.70 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 47.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
Secondary
C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 36.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 36.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 36.75 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 43.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 39.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | 33.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 37.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | 42.70 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 52.55 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 51.65 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 47.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 23.90 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 24.95 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 37.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 42.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 50.75 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 44.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 59.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 11 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 42.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 33.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 33.90 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 39.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 63.95 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 68.80 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | 54.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 67.85 ug/mL |
Secondary
Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT])
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 27.5 Score on scale | Standard Deviation 16.65 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -14.8 Score on scale | Standard Deviation 17.86 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 45.0 Score on scale | Standard Deviation 25.45 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | -11.4 Score on scale | Standard Deviation 15.19 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 83.3 Score on scale | Standard Deviation 17.57 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -11.1 Score on scale | Standard Deviation 50.92 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 58.9 Score on scale | Standard Deviation 29.65 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -7.4 Score on scale | Standard Deviation 51.32 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 38.9 Score on scale | Standard Deviation 39.28 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 21.0 Score on scale | Standard Deviation 18.64 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 24.1 Score on scale | Standard Deviation 22.45 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 48.1 Score on scale | Standard Deviation 12.83 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -8.3 Score on scale | Standard Deviation 27.5 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 100.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | -14.8 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 19.9 Score on scale | Standard Deviation 11.2 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -8.3 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 10.0 Score on scale | Standard Deviation 9.34 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 26.6 Score on scale | Standard Deviation 12.22 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 0.1 Score on scale | Standard Deviation 7.86 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 58.9 Score on scale | Standard Deviation 28.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 76.7 Score on scale | Standard Deviation 31.62 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 13.9 Score on scale | Standard Deviation 13.98 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 24.7 Score on scale | Standard Deviation 19.47 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 18.8 Score on scale | Standard Deviation 13.87 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -5.6 Score on scale | Standard Deviation 36 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 81.5 Score on scale | Standard Deviation 24.22 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 8.3 Score on scale | Standard Deviation 41.94 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 72.8 Score on scale | Standard Deviation 16.77 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 0.0 Score on scale | Standard Deviation 9.07 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -6.7 Score on scale | Standard Deviation 21.66 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 23.6 Score on scale | Standard Deviation 13.79 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 77.8 Score on scale | Standard Deviation 29.59 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 23.3 Score on scale | Standard Deviation 26.76 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 40.7 Score on scale | Standard Deviation 19.58 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 0.0 Score on scale | Standard Deviation 14.6 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 65.7 Score on scale | Standard Deviation 17.38 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 6.7 Score on scale | Standard Deviation 14.91 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 21.0 Score on scale | Standard Deviation 19.4 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 1.9 Score on scale | Standard Deviation 7.86 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 0.0 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 67.9 Score on scale | Standard Deviation 17.07 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 7.7 Score on scale | Standard Deviation 6.87 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 85.2 Score on scale | Standard Deviation 24.22 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -2.8 Score on scale | Standard Deviation 19.64 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 1.9 Score on scale | Standard Deviation 14.77 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 3.3 Score on scale | Standard Deviation 5 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 55.6 Score on scale | Standard Deviation 31.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 21.2 Score on scale | Standard Deviation 17.88 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -8.3 Score on scale | Standard Deviation 10.39 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 12.7 Score on scale | Standard Deviation 9.65 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 69.7 Score on scale | Standard Deviation 37.87 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 31.5 Score on scale | Standard Deviation 21.15 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 5.6 Score on scale | Standard Deviation 22.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 15.1 Score on scale | Standard Deviation 9.43 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -3.2 Score on scale | Standard Deviation 22.87 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 19.0 Score on scale | Standard Deviation 19.38 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 88.9 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -9.5 Score on scale | Standard Deviation 16.27 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 59.3 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 29.0 Score on scale | Standard Deviation 23.37 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 14.9 Score on scale | Standard Deviation 6.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 77.8 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -5.6 Score on scale | Standard Deviation 7.86 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 5.6 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 1.1 Score on scale | Standard Deviation 6.81 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 58.0 Score on scale | Standard Deviation 34.15 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 26.7 Score on scale | Standard Deviation 15.89 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 62.2 Score on scale | Standard Deviation 15 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | -2.7 Score on scale | Standard Deviation 8.74 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | -2.8 Score on scale | Standard Deviation 18.43 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 16.7 Score on scale | Standard Deviation 14.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 90.0 Score on scale | Standard Deviation 22.5 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -8.3 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 93.3 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | -8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | -2.8 Score on scale | Standard Deviation 44.79 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 5.6 Score on scale | Standard Deviation 8.74 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 63.3 Score on scale | Standard Deviation 16.6 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 13.9 Score on scale | Standard Deviation 13.6 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 12.5 Score on scale | Standard Deviation 20.48 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 25.6 Score on scale | Standard Deviation 20.15 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, CFB to EoT | 4.2 Score on scale | Standard Deviation 13.13 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, Baseline (Day 1) | 11.3 Score on scale | Standard Deviation 8.99 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | SET, CFB to EoT | 6.5 Score on scale | Standard Deviation 20.14 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | DS, Baseline (Day 1) | 18.8 Score on scale | Standard Deviation 8.88 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | BI, Baseline (Day 1) | 75.0 Score on scale | Standard Deviation 34.5 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, CFB to EoT | 22.2 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score | FP, Baseline (Day 1) | 66.7 Score on scale | Standard Deviation 13.28 |
Secondary
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT])
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 22.2 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 75.0 Score on scale | Standard Deviation 16.2 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 20.0 Score on scale | Standard Deviation 28.11 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 5.6 Score on scale | Standard Deviation 29.27 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 46.7 Score on scale | Standard Deviation 35.83 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 76.7 Score on scale | Standard Deviation 25.4 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 66.7 Score on scale | Standard Deviation 30.43 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | 0.0 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 67.3 Score on scale | Standard Deviation 23.82 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 33.3 Score on scale | Standard Deviation 35.14 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 46.7 Score on scale | Standard Deviation 23.89 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 3.7 Score on scale | Standard Deviation 35.72 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -27.8 Score on scale | Standard Deviation 63.1 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -50.0 Score on scale | Standard Deviation 22.05 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 33.3 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 11.7 Score on scale | Standard Deviation 15.81 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 30.0 Score on scale | Standard Deviation 33.15 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 65.8 Score on scale | Standard Deviation 25.29 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 71.7 Score on scale | Standard Deviation 26.12 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 23.3 Score on scale | Standard Deviation 27.44 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -22.2 Score on scale | Standard Deviation 69.39 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 11.1 Score on scale | Standard Deviation 41.94 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 40.0 Score on scale | Standard Deviation 26.29 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -16.7 Score on scale | Standard Deviation 44.1 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 22.2 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 33.3 Score on scale | Standard Deviation 57.74 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -17.8 Score on scale | Standard Deviation 48.23 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 86.1 Score on scale | Standard Deviation 4.81 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 25.9 Score on scale | Standard Deviation 16.97 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | -11.1 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 33.3 Score on scale | Standard Deviation 47.14 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | -12.5 Score on scale | Standard Deviation 5.89 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 88.9 Score on scale | Standard Deviation 9.62 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 88.9 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 69.4 Score on scale | Standard Deviation 31.55 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 44.4 Score on scale | Standard Deviation 38.49 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 47.14 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | 4.2 Score on scale | Standard Deviation 17.68 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | 8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -16.7 Score on scale | Standard Deviation 47.14 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 88.9 Score on scale | Standard Deviation 13.88 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 22.2 Score on scale | Standard Deviation 25.46 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | 13.3 Score on scale | Standard Deviation 18.86 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 88.9 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 58.3 Score on scale | Standard Deviation 14.16 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -12.5 Score on scale | Standard Deviation 15.96 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 36.7 Score on scale | Standard Deviation 24.6 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 31.1 Score on scale | Standard Deviation 8.76 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 30.0 Score on scale | Standard Deviation 36.68 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | 0.0 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 33.3 Score on scale | Standard Deviation 27.22 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 5.6 Score on scale | Standard Deviation 6.42 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 25.0 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -6.7 Score on scale | Standard Deviation 24.94 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -4.2 Score on scale | Standard Deviation 14.43 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 13.3 Score on scale | Standard Deviation 17.21 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 11.7 Score on scale | Standard Deviation 15.81 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 8.3 Score on scale | Standard Deviation 34.69 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 71.7 Score on scale | Standard Deviation 24.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 8.3 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 78.7 Score on scale | Standard Deviation 15.65 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | -16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 16.7 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 80.0 Score on scale | Standard Deviation 18.92 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 76.7 Score on scale | Standard Deviation 22.5 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 77.5 Score on scale | Standard Deviation 18.02 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 8.3 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 4.2 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 4.2 Score on scale | Standard Deviation 34.36 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 72.9 Score on scale | Standard Deviation 21.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | -16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 37.5 Score on scale | Standard Deviation 31.81 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 25.0 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 12.5 Score on scale | Standard Deviation 20.97 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 2.1 Score on scale | Standard Deviation 5.89 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 27.22 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 77.1 Score on scale | Standard Deviation 21.71 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 60.4 Score on scale | Standard Deviation 13.18 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 38.9 Score on scale | Standard Deviation 19.7 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 29.2 Score on scale | Standard Deviation 21.36 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 12.5 Score on scale | Standard Deviation 17.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | 0.0 Score on scale | Standard Deviation 33.11 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -16.7 Score on scale | Standard Deviation 18 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 72.9 Score on scale | Standard Deviation 29.46 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -12.5 Score on scale | Standard Deviation 36.96 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -25.0 Score on scale | Standard Deviation 50 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | -4.2 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 2.8 Score on scale | Standard Deviation 24.64 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 76.0 Score on scale | Standard Deviation 16.93 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 16.7 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 73.3 Score on scale | Standard Deviation 21.97 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 10.4 Score on scale | Standard Deviation 15.77 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 12.5 Score on scale | Standard Deviation 17.25 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 15.43 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -6.7 Score on scale | Standard Deviation 25.28 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 19.4 Score on scale | Standard Deviation 22.29 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 56.2 Score on scale | Standard Deviation 23.33 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 3.3 Score on scale | Standard Deviation 33.64 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 75.0 Score on scale | Standard Deviation 15.6 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | -6.7 Score on scale | Standard Deviation 30.28 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 16.7 Score on scale | Standard Deviation 26.59 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 13.3 Score on scale | Standard Deviation 28.76 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 0.0 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 70.8 Score on scale | Standard Deviation 20.87 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | -13.3 Score on scale | Standard Deviation 29.81 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 76.4 Score on scale | Standard Deviation 20.67 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -6.7 Score on scale | Standard Deviation 25.28 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 34.3 Score on scale | Standard Deviation 19.22 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | -6.7 Score on scale | Standard Deviation 27.89 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 22.2 Score on scale | Standard Deviation 25.95 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 68.1 Score on scale | Standard Deviation 21.86 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -10.0 Score on scale | Standard Deviation 25.28 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | -13.3 Score on scale | Standard Deviation 18.26 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 41.7 Score on scale | Standard Deviation 26.11 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -10.0 Score on scale | Standard Deviation 34.05 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 81.9 Score on scale | Standard Deviation 19.41 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 36.1 Score on scale | Standard Deviation 30.01 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -5.3 Score on scale | Standard Deviation 22.8 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | 20.0 Score on scale | Standard Deviation 36.13 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 15.08 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 36.1 Score on scale | Standard Deviation 33.21 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 13.9 Score on scale | Standard Deviation 22.29 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 7.4 Score on scale | Standard Deviation 14.7 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 72.2 Score on scale | Standard Deviation 22.05 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -8.3 Score on scale | Standard Deviation 35.36 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 94.4 Score on scale | Standard Deviation 7.22 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 87.0 Score on scale | Standard Deviation 13.89 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 83.3 Score on scale | Standard Deviation 18.63 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 67.6 Score on scale | Standard Deviation 9.72 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -16.7 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 84.4 Score on scale | Standard Deviation 17.95 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -10.0 Score on scale | Standard Deviation 14.14 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 28.4 Score on scale | Standard Deviation 21.6 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | -11.1 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 3.7 Score on scale | Standard Deviation 7.35 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | -8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 24.1 Score on scale | Standard Deviation 29 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 25.9 Score on scale | Standard Deviation 14.7 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 47.14 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | -16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 7.4 Score on scale | Standard Deviation 14.7 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | -5.6 Score on scale | Standard Deviation 13.61 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 81.8 Score on scale | Standard Deviation 17.41 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 12.1 Score on scale | Standard Deviation 16.82 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 0.0 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 29.3 Score on scale | Standard Deviation 13.4 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 85.5 Score on scale | Standard Deviation 17.34 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 28.8 Score on scale | Standard Deviation 25.92 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 24.2 Score on scale | Standard Deviation 36.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -11.1 Score on scale | Standard Deviation 22.77 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 81.8 Score on scale | Standard Deviation 24.1 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -5.6 Score on scale | Standard Deviation 8.61 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | 0.0 Score on scale | Standard Deviation 13.94 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | -5.6 Score on scale | Standard Deviation 13.61 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -11.1 Score on scale | Standard Deviation 27.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 15.2 Score on scale | Standard Deviation 17.41 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 4.5 Score on scale | Standard Deviation 7.78 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 9.1 Score on scale | Standard Deviation 15.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -1.1 Score on scale | Standard Deviation 9.81 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 63.6 Score on scale | Standard Deviation 20.84 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 27.3 Score on scale | Standard Deviation 25.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 73.5 Score on scale | Standard Deviation 25.5 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 77.3 Score on scale | Standard Deviation 28.16 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | -3.7 Score on scale | Standard Deviation 13.46 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 5.6 Score on scale | Standard Deviation 25.09 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 5.6 Score on scale | Standard Deviation 17.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 2.8 Score on scale | Standard Deviation 6.8 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 12.1 Score on scale | Standard Deviation 16.82 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 56.1 Score on scale | Standard Deviation 20.78 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 9.1 Score on scale | Standard Deviation 15.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -14.6 Score on scale | Standard Deviation 25.88 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 6.3 Score on scale | Standard Deviation 12.4 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 4.2 Score on scale | Standard Deviation 21.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 9.1 Score on scale | Standard Deviation 15.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 68.9 Score on scale | Standard Deviation 28.89 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 4.2 Score on scale | Standard Deviation 21.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 74.2 Score on scale | Standard Deviation 15.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -12.5 Score on scale | Standard Deviation 27.93 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 8.3 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 0.0 Score on scale | Standard Deviation 32.12 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 71.2 Score on scale | Standard Deviation 28.95 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | -4.2 Score on scale | Standard Deviation 21.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | 12.5 Score on scale | Standard Deviation 30.54 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 1.5 Score on scale | Standard Deviation 5.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 33.3 Score on scale | Standard Deviation 36.51 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | -6.3 Score on scale | Standard Deviation 25.49 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 57.6 Score on scale | Standard Deviation 36.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 12.5 Score on scale | Standard Deviation 39.59 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 21.2 Score on scale | Standard Deviation 34.23 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 34.3 Score on scale | Standard Deviation 26.51 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 0.0 Score on scale | Standard Deviation 17.82 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 16.7 Score on scale | Standard Deviation 33.6 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 70.9 Score on scale | Standard Deviation 25.69 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 33.3 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 15.2 Score on scale | Standard Deviation 17.41 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 30.86 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 34.8 Score on scale | Standard Deviation 34.52 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -27.1 Score on scale | Standard Deviation 36.66 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 42.6 Score on scale | Standard Deviation 33.45 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -4.2 Score on scale | Standard Deviation 17.68 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 70.4 Score on scale | Standard Deviation 33.1 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 11.1 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | 8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 14.8 Score on scale | Standard Deviation 24.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | 3.3 Score on scale | Standard Deviation 4.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 60.2 Score on scale | Standard Deviation 26.61 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 22.2 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 7.4 Score on scale | Standard Deviation 22.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 74.1 Score on scale | Standard Deviation 16.9 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 47.14 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 72.2 Score on scale | Standard Deviation 34.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 16.7 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | -12.5 Score on scale | Standard Deviation 5.89 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 25.9 Score on scale | Standard Deviation 27.78 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 83.3 Score on scale | Standard Deviation 13.18 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 5.6 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 66.7 Score on scale | Standard Deviation 31.27 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 30.9 Score on scale | Standard Deviation 30.32 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 37.0 Score on scale | Standard Deviation 38.89 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | 8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 26.7 Score on scale | Standard Deviation 37.84 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 11.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -10.0 Score on scale | Standard Deviation 15.87 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | -4.2 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 78.7 Score on scale | Standard Deviation 19.58 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 28.3 Score on scale | Standard Deviation 20.86 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | -8.3 Score on scale | Standard Deviation 9.62 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | 25.0 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 16.7 Score on scale | Standard Deviation 17.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 55.0 Score on scale | Standard Deviation 24.6 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 68.3 Score on scale | Standard Deviation 34.65 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 33.3 Score on scale | Standard Deviation 31.43 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -8.3 Score on scale | Standard Deviation 21.52 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | -16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 26.7 Score on scale | Standard Deviation 26.29 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 83.3 Score on scale | Standard Deviation 22.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | -8.3 Score on scale | Standard Deviation 41.94 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 2.1 Score on scale | Standard Deviation 14.23 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 13.3 Score on scale | Standard Deviation 17.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 78.3 Score on scale | Standard Deviation 17.21 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -20.8 Score on scale | Standard Deviation 34.36 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 21.08 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 73.3 Score on scale | Standard Deviation 19.56 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 27.22 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 32.2 Score on scale | Standard Deviation 23.1 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | 2.8 Score on scale | Standard Deviation 18.98 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | 20.8 Score on scale | Standard Deviation 36.96 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 83.3 Score on scale | Standard Deviation 16.2 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 20.0 Score on scale | Standard Deviation 35.83 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 95.0 Score on scale | Standard Deviation 8.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 54.43 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -16.7 Score on scale | Standard Deviation 27.22 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | -25.0 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 30.0 Score on scale | Standard Deviation 33.15 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 63.3 Score on scale | Standard Deviation 16.29 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 16.7 Score on scale | Standard Deviation 17.57 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 5.0 Score on scale | Standard Deviation 8.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 73.3 Score on scale | Standard Deviation 17.92 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 71.7 Score on scale | Standard Deviation 22.29 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | -2.8 Score on scale | Standard Deviation 41.94 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | -4.2 Score on scale | Standard Deviation 43.83 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | 18.7 Score on scale | Standard Deviation 23.94 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -11.7 Score on scale | Standard Deviation 42.64 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | 8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 36.7 Score on scale | Standard Deviation 25.82 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 37.8 Score on scale | Standard Deviation 25.77 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | -12.5 Score on scale | Standard Deviation 34.36 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 82.0 Score on scale | Standard Deviation 10.91 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | -12.5 Score on scale | Standard Deviation 15.96 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | 25.0 Score on scale | Standard Deviation 50 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 6.7 Score on scale | Standard Deviation 14.05 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 4.2 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 20.0 Score on scale | Standard Deviation 32.2 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, Baseline (Day 1) | 67.7 Score on scale | Standard Deviation 15.71 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, CFB to EoT | 8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, CFB to EoT | -16.7 Score on scale | Standard Deviation 33.33 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, Baseline (Day 1) | 91.7 Score on scale | Standard Deviation 12.6 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | FD, Baseline (Day 1) | 20.8 Score on scale | Standard Deviation 35.36 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, CFB to EoT | -8.3 Score on scale | Standard Deviation 31.91 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | CF, CFB to EoT | -8.3 Score on scale | Standard Deviation 9.62 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, Baseline (Day 1) | 89.4 Score on scale | Standard Deviation 11.48 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, CFB to EoT | 0.0 Score on scale | Standard Deviation 0 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, CFB to EoT | 16.7 Score on scale | Standard Deviation 19.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Insomnia, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 15.43 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, CFB to EoT | -4.2 Score on scale | Standard Deviation 28.46 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, Baseline (Day 1) | 91.7 Score on scale | Standard Deviation 8.91 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, Baseline (Day 1) | 2.1 Score on scale | Standard Deviation 5.89 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | EF, CFB to EoT | 6.3 Score on scale | Standard Deviation 12.5 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | GHS/QoL, CFB to EoT | 4.2 Score on scale | Standard Deviation 20.97 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Dyspnoea, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 15.43 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | PF, CFB to EoT | -1.7 Score on scale | Standard Deviation 12.62 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | N/V, CFB to EoT | 0.0 Score on scale | Standard Deviation 13.61 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, Baseline (Day 1) | 12.5 Score on scale | Standard Deviation 24.8 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Pain, Baseline (Day 1) | 22.9 Score on scale | Standard Deviation 21.71 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Diarrhoea, Baseline (Day 1) | 12.5 Score on scale | Standard Deviation 17.25 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | AL, CFB to EoT | -8.3 Score on scale | Standard Deviation 16.67 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | SF, Baseline (Day 1) | 75.0 Score on scale | Standard Deviation 23.57 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | RF, Baseline (Day 1) | 89.6 Score on scale | Standard Deviation 19.8 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, Baseline (Day 1) | 31.9 Score on scale | Standard Deviation 3.93 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Constipation, Baseline (Day 1) | 8.3 Score on scale | Standard Deviation 15.43 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score | Fatigue, CFB to EoT | -11.1 Score on scale | Standard Deviation 12.83 |
Secondary
Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores
The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. OSDI consist of three subscales (ocular symptoms: item 1-3; visual related function: item 4-9; environmental triggers: item 10-12). Each item will be graded on a scale of 0 (none of the time or lower disability) to 4 (all of the time or greater disability) with total scores ranging from 0 (no disability) to 100 (complete disability). The total OSDI score was calculated as (sum of scores for all questions answered\*100) divided by (total number of questions answered\*4). Higher scores indicated greater disability. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 11.1 Score on scale | Standard Deviation 7.58 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | -5.2 Score on scale | Standard Deviation 4.42 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 0.8 Score on scale | Standard Deviation 1.56 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 0.6 Score on scale | Standard Deviation 4.1 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 7.8 Score on scale | Standard Deviation 9.3 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 6.9 Score on scale | Standard Deviation 12.03 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 11.4 Score on scale | Standard Deviation 14.26 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 2.2 Score on scale | Standard Deviation 7.19 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 15.2 Score on scale | Standard Deviation 35.94 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 10.8 Score on scale | Standard Deviation 17.2 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 2.4 Score on scale | Standard Deviation 2.79 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 15.9 Score on scale | Standard Deviation 14.8 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 18.7 Score on scale | Standard Deviation 34.95 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 7.8 Score on scale | Standard Deviation 9.94 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 8.0 Score on scale | Standard Deviation 5.66 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 29.3 Score on scale | Standard Deviation 39.18 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 12.4 Score on scale | Standard Deviation 16.42 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 6.1 Score on scale | Standard Deviation 8.59 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 6.3 Score on scale | Standard Deviation 7.71 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 14.4 Score on scale | Standard Deviation 23.26 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 48.3 Score on scale | Standard Deviation 27.42 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 8.6 Score on scale | Standard Deviation 13.61 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Change from baseline (up to approx. 4.5 years) | 19.3 Score on scale | Standard Deviation 14.41 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in Ocular Surface Disease Index (OSDI) Total Scores | Baseline (Day 1) | 3.3 Score on scale | Standard Deviation 5.58 |
Secondary
Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores
The NEI-VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question to assess the patient's perception of vision-related functioning and vision-related quality of life. Items were coded to a 0 to 100 scale and were averaged to calculate domains. The composite score ranges from 0 (worst score) to 100 (best score), with higher scores indicating better vision-related functioning. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | 0.2 Score on scale | Standard Deviation 13.53 |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 85.1 Score on scale | Standard Deviation 11.42 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 89.0 Score on scale | Standard Deviation 18.43 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | 12.9 Score on scale | Standard Deviation 22.42 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 91.9 Score on scale | Standard Deviation 10.88 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -4.5 Score on scale | Standard Deviation 4.04 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -1.9 Score on scale | Standard Deviation 3.43 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 91.0 Score on scale | Standard Deviation 11.35 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | 1.1 Score on scale | Standard Deviation 19.48 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 88.0 Score on scale | Standard Deviation 16.92 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 95.5 Score on scale | Standard Deviation 4.7 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -8.4 Score on scale | Standard Deviation 13.65 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -18.3 Score on scale | Standard Deviation 19.96 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 96.2 Score on scale | Standard Deviation 5.2 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -26.0 Score on scale | Standard Deviation 31.54 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 95.3 Score on scale | Standard Deviation 4.6 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | 1.3 Score on scale | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 90.4 Score on scale | Standard Deviation 7.67 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -13.2 Score on scale | Standard Deviation 25 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 94.1 Score on scale | Standard Deviation 8.33 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 93.2 Score on scale | Standard Deviation 7.13 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -48.9 Score on scale | Standard Deviation 2.35 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Change from baseline (up to approx. 4.5 years) | -11.5 Score on scale | Standard Deviation 15.39 |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Scores | Baseline (Day 1) | 94.7 Score on scale | Standard Deviation 5.59 |
Secondary
Cmax for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 52.24 ug/mL | Geometric Coefficient of Variation 31.87 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 49.50 ug/mL | Geometric Coefficient of Variation 21.38 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 61.16 ug/mL | Geometric Coefficient of Variation 36.74 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 51.29 ug/mL | Geometric Coefficient of Variation 26.03 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 24.46 ug/mL | Geometric Coefficient of Variation 32.1 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 21.34 ug/mL | Geometric Coefficient of Variation 34.67 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 46.95 ug/mL | Geometric Coefficient of Variation 23.24 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 27.79 ug/mL | Geometric Coefficient of Variation 37.28 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 31.96 ug/mL | Geometric Coefficient of Variation 32.79 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 64.00 ug/mL | Geometric Coefficient of Variation 38.6 |
Secondary
Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 0.73 ug/mL | Geometric Coefficient of Variation 29.88 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 0.75 ug/mL | Geometric Coefficient of Variation 68.94 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 1.03 ug/mL | Geometric Coefficient of Variation 52.77 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 1.29 ug/mL | Geometric Coefficient of Variation 38.95 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 8 | 0.58 ug/mL | Geometric Coefficient of Variation 87.48 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 0.65 ug/mL | Geometric Coefficient of Variation 87.99 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 1.15 ug/mL | Geometric Coefficient of Variation 57.18 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 1.03 ug/mL | Geometric Coefficient of Variation 38.56 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 8 | 0.86 ug/mL | Geometric Coefficient of Variation 64.55 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Cys-mcMMAF) Treatment B | CYCLE 1 DAY 1 | 1.09 ug/mL | Geometric Coefficient of Variation 40.3 |
Secondary
Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 1.11 ug/mL | Geometric Coefficient of Variation 70.59 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.55 ug/mL | Geometric Coefficient of Variation 53.9 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 0.53 ug/mL | Geometric Coefficient of Variation 48.23 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 8 | 0.63 ug/mL | Geometric Coefficient of Variation 28.28 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 1.18 ug/mL | Geometric Coefficient of Variation 53.35 |
Secondary
Cmax for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 43.09 ug/mL | Geometric Coefficient of Variation 22.26 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 40.18 ug/mL | Geometric Coefficient of Variation 13.23 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 26.64 ug/mL | Geometric Coefficient of Variation 14.97 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 8 | 35.11 ug/mL | Geometric Coefficient of Variation 13.68 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 46.95 ug/mL | Geometric Coefficient of Variation 30.63 |
Secondary
Cmax for Belantamab Mafodotin (Total Antibody) Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 41.28 ug/mL | Geometric Coefficient of Variation 16.86 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 37.47 ug/mL | Geometric Coefficient of Variation 12.02 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 53.29 ug/mL | Geometric Coefficient of Variation 23.5 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 53.85 ug/mL | Geometric Coefficient of Variation 12.54 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 8 | 29.47 ug/mL | Geometric Coefficient of Variation 40.48 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 22.92 ug/mL | Geometric Coefficient of Variation 35.83 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 50.32 ug/mL | Geometric Coefficient of Variation 30.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 8 | 45.31 ug/mL | Geometric Coefficient of Variation 39.57 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 31.06 ug/mL | Geometric Coefficient of Variation 20.02 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Cmax for Belantamab Mafodotin (Total Antibody) Treatment B | CYCLE 1 DAY 1 | 78.29 ug/mL | Geometric Coefficient of Variation 36.16 |
Secondary
Cmax for Bortezomib, Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 Hours Post-Dose on Cycle 1 Day 1
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points for Bortezomib have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Bortezomib, Treatment B | SUBCUTANEOUS | 14.45 ug/mL | Geometric Coefficient of Variation 50.16 |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Cmax for Bortezomib, Treatment B | INTRAVENOUS | NA ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Cmax for Bortezomib, Treatment B | SUBCUTANEOUS | 14.89 ug/mL | Geometric Coefficient of Variation 44.03 |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Cmax for Bortezomib, Treatment B | INTRAVENOUS | NA ug/mL | — |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Cmax for Bortezomib, Treatment B | SUBCUTANEOUS | 15.88 ug/mL | Geometric Coefficient of Variation 42.07 |
Secondary
Cmax for Lenalidomide (10 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 10 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Lenalidomide (10 mg), Treatment A | 193.06 ug/mL | Geometric Coefficient of Variation 36.86 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Lenalidomide (10 mg), Treatment A | NA ug/mL | — |
Secondary
Cmax for Lenalidomide (25 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 25 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Cmax for Lenalidomide (25 mg), Treatment A | 382.16 ug/mL | Geometric Coefficient of Variation 54.52 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Cmax for Lenalidomide (25 mg), Treatment A | 331.53 ug/mL | Geometric Coefficient of Variation 17.91 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Cmax for Lenalidomide (25 mg), Treatment A | 283.08 ug/mL | Geometric Coefficient of Variation 36.55 |
Secondary
Ctrough for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.12 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 3.90 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.92 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 3.23 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 0.63 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 1.24 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | 1.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 0.84 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 3.72 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 3.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 4.39 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 5.85 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 2.12 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 1.32 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 2.72 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 7 DAY 1 | 10.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 3.62 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 3.93 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 4.25 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | WEEK 4 DAY 1 | 2.53 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 2.10 ug/mL |
Secondary
Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 5 Day 1, Week 5 Day 8, Week 9 Day 1, Week 9 Day 8, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 0.81 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 2.76 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 3.39 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 7.74 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 8 | 3.99 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 12.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 8 | 6.16 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | 15.25 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 8 | 10.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 13 DAY 1 | 10.70 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 5 DAY 1 | 1.82 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 3.16 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment A | WEEK 9 DAY 1 | NA ug/mL |
Secondary
Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 3.13 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 7.97 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 5.27 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 7.66 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 1.72 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 1.53 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | 3.07 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | 5.26 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 1.32 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 2.32 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 5.88 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 12.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 19.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 14.95 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 1.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 7.22 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 3.62 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 12.05 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 11.20 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 9.59 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 7 DAY 1 | 26.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 6.82 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 4 DAY 1 | 5.27 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B | WEEK 10 DAY 1 | NA ug/mL |
Secondary
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A
Blood samples were collected at indicated timepoints for pharmacokinetic (PK) analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population included all participants in all treated population from whom at least one PK sample was obtained, analyzed, and was measurable. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | CYCLE 1 DAY 1 | 43.58 Microgram/ millilitre (ug/mL) | Geometric Coefficient of Variation 21.78 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | CYCLE 1 DAY 1 | 36.41 Microgram/ millilitre (ug/mL) | Geometric Coefficient of Variation 17.06 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | CYCLE 1 DAY 1 | 25.22 Microgram/ millilitre (ug/mL) | Geometric Coefficient of Variation 16.53 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | CYCLE 1 DAY 8 | 27.60 Microgram/ millilitre (ug/mL) | Geometric Coefficient of Variation 16.27 |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A | CYCLE 1 DAY 1 | 39.99 Microgram/ millilitre (ug/mL) | Geometric Coefficient of Variation 25.03 |
Secondary
Number of Participants With AEs of Special Interest (AESI)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with AESI for belantamab mafodotin (corneal events, thrombocytopenia and infusion related reactions) are presented.
Time frame: Up to approximately 4.5 years
Population: All Treated population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Infusion Related Reactions) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Corneal Events) | 16 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With AEs of Special Interest (AESI) | AESI (Thrombocytopenia) | 14 Participants |
Secondary
Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin using validated immunoassays.
Time frame: Up to approximately 4.5 years (End of Treatment [EoT])
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | EoT (Up to approx. 4.5 years) | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | Baseline (Day 1) | 0 Participants |
Secondary
Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception
Number of participants with a Decline in BCVA to 'Light Perception (LP)' or 'No Light Perception (NLP)' due to a Corneal Event Anytime Post-Baseline are presented. BCVA score was assessed individually for each eye (Left and Right). Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Number of participants analyzed were who have any post-baseline BCVA score, where the Visual Acuity is due to corneal findings.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, LP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Left Eye, NLP | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception | Right Eye, NLP | 0 Participants |
Secondary
Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline)
Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Corneal epithelium findings like active edema, active opacity, corneal neovascularization (CN), corneal ulcer, epithelial microcystic edema (EME) and subepithelial haze were performed using a slit lamp. Number of participants with shift in corneal epithelium findings from no (Baseline) to yes (worst post-Baseline) are presented.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Left Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Epithelial Microcystic Edema, Right Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Left Eye | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Right Eye | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Ulcer, Left Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Edema, Right Eye | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Right Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Subepithelial Haze, Left Eye | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Corneal Neovascularization, Left Eye | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline) | Active Opacity, Right Eye | 1 Participants |
Secondary
Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. It included item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE like Anxious, Blurred Vision, Chills, Concentration, Constipation, Cough, Decreased Appetite, Discouraged, Dizziness, Fatigue, Heart Palpitations, Insomnia, Memory, Mouth/Throat Sores, Nausea, Nosebleed, Numbness & Tingling, Pain, Ringing In Ears, Shortness Of Breath, Vomiting and Watery Eyes. Number of participants with symptomatic AEs measured by PRO-CTCAEs are presented.
Time frame: Up to approximately 4.5 years
Population: All Treated.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 17 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Decreased Appetite | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nosebleed | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Chills | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Insomnia | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Cough | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numbness & tingling | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Memory | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Blurred Vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Ringing In Ears | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Discouraged | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Dizziness | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxious | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Heart Palpitations | 15 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Watery Eyes | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Shortness Of Breath | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Concentration | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Mouth/Throat Sores | 0 Participants |
Secondary
Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings
Participants with worse grade punctate keratopathy findings post baseline at any ocular exam by right eye, left eye and worse eye are presented as none, mild, moderate and severe. Worse eye indicates the eye with the worst visual acuity. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, None | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Moderate | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Mild | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Moderate | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Severe | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, Moderate | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Left Eye, None | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Worst eye, Severe | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worse Grade Post-baseline Punctate Keratopathy Findings | Right Eye, Mild | 2 Participants |
Secondary
Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores
BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 13 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Definite worsened vision | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Possible worsened vision | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, No change/improved vision | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Right Eye, Possible worsened vision | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, No change/improved vision | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores | Left Eye, Definite worsened vision | 8 Participants |
Secondary
Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results
BCVA score was assessed individually for better seeing eye and worse seeing eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change post baseline categories are presented for better seeing eye and worse seeing eye. BCVA test scores by Snellen results were categorized as improved BCVA, \<= 2 lines decline in visual acuity from baseline, \>= 3 lines decline in visual acuity from baseline. Number of lines change from baseline was defined as the following: Improved BCVA equates to a negative change in logMAR from baseline BCVA. \<= 2 lines decline in visual acuity equates to logMAR change from baseline ≤0.37. \>= 3 lines decline in visual acuity equates to logMAR change from baseline ≥0.38. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 11 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 3 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 10 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 5 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 6 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 1 Participants |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 2 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 9 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 7 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, >=3 Lines decline in visual acuity from baseline | 4 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, <=2 Lines decline in visual acuity from baseline | 8 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Better seeing Eye, <=2 Lines decline in visual acuity from baseline | 12 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, Improved BCVA | 0 Participants |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex | Number of Participants With Worst-case Post-baseline Change in BCVA Scores by Snellen Results | Worse seeing Eye, >=3 Lines decline in visual acuity from baseline | 8 Participants |
Secondary
Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and Day 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 39.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | 42.35 ug/mL |
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 36.05 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | 35.45 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 8 | 27.10 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 25.05 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 8 | 26.55 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | 23.00 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | 23.50 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 8 | 25.60 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | 38.40 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | 36.75 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Observed Plasma Concentration at the End of Infusion (C-EOI) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 41.80 ug/mL |
Secondary
Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 29; pre-dose Cycle 2 Day 28
Population: Pharmacokinetic (PK) population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A | 181.467 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A | 685.608 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A | 674.833 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Time of Last Observed Quantifiable Concentration (Tlast) for Belantamab Mafodotin ADC, Treatment A | 671.717 Hour |
Secondary
Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 2.050 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 1.342 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 1.100 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 8 | 1.108 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Time to Reach Maximum Observed Concentration (Tmax) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 2.000 Hour |
Secondary
Titers of ADAs Against Belantamab Mafodotin
Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin using validated immunoassays. Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.
Time frame: Up to approximately 4.5 years
Population: All Treated. Only those participants with data available at specified time points have been analyzed. There were no participants with positive ADA results at end of treatment. Hence the titer (concentration) of ADA was not collected.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Titers of ADAs Against Belantamab Mafodotin | 100 Titers |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex | Titers of ADAs Against Belantamab Mafodotin | 100 Titers |
| Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex | Titers of ADAs Against Belantamab Mafodotin | 100 Titers |
Secondary
Tlast for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Time frame: Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 5 Day 1
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 540.250 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 505.592 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 1009.933 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 755.442 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 504.567 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 506.817 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 503.458 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin ADC, Treatment B | 506.092 Hour |
Secondary
Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 1 Day 15
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | 165.567 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | 120.283 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | 336.900 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | 166.167 Hour |
Secondary
Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Time frame: Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 2 Day 1
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 85.542 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 239.800 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 237.992 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 93.942 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 241.283 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 237.425 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 240.675 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | 171.567 Hour |
Secondary
Tlast for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 15-21; Cycle 1 Day 29; pre-dose Cycle 2 Day 28; pre-dose Cycle 3 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment A | 657.267 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment A | 685.875 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment A | 674.833 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment A | 673.625 Hour |
Secondary
Tlast for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. Tlast is the time of last observed quantifiable concentration of belantamab mafodotin in Cycle 1 which extended beyond protocol defined duration for some participants across treatment groups.
Time frame: Pre-Dose Cycle 1 Day 1 to pre-dose Cycle 9 Day 1
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 585.958 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 504.983 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 1414.500 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 1031.467 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 504.583 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 505.483 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 502.883 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tlast for Belantamab Mafodotin (Total Antibody), Treatment B | 506.808 Hour |
Secondary
Tlast for Bortezomib, Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post dose on Cycle 1 Day 3
Population: Pharmacokinetic (PK) population. Only those participants who received Bortezomib with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Bortezomib, Treatment B | Subcutaneous | 68.867 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tlast for Bortezomib, Treatment B | Subcutaneous | NA Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tlast for Bortezomib, Treatment B | Intravenous | NA Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tlast for Bortezomib, Treatment B | Subcutaneous | 68.392 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tlast for Bortezomib, Treatment B | Intravenous | NA Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tlast for Bortezomib, Treatment B | Subcutaneous | 48.000 Hour |
Secondary
Tlast for Lenalidomide (10 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post dose on Cycle 1 Day 1
Population: Pharmacokinetic (PK) population. Only those participants who received 10 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Lenalidomide (10 mg), Treatment A | 21.583 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Lenalidomide (10 mg), Treatment A | NA Hour |
Secondary
Tlast for Lenalidomide (25 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, Post dose on Cycle 1 Day 1
Population: Pharmacokinetic (PK) population. Only those participants who received 25 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tlast for Lenalidomide (25 mg), Treatment A | 20.750 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tlast for Lenalidomide (25 mg), Treatment A | 4.000 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tlast for Lenalidomide (25 mg), Treatment A | 22.050 Hour |
Secondary
Tmax for Belantamab Mafodotin ADC, Treatment B
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.900 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.125 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 2.025 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.175 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 0.733 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.233 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 1.308 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 0.583 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 8 | 0.642 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin ADC, Treatment B | CYCLE 1 DAY 1 | 2.000 Hour |
Secondary
Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 24.217 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 24.900 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 23.667 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 8 | 23.425 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment A | CYCLE 1 DAY 1 | 24.367 Hour |
Secondary
Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 22.225 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 24.475 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 23.092 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 22.442 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 8 | 24.000 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 24.083 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 24.083 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 24.583 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 8 | 23.717 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Cys-mcMMAF), Treatment B | CYCLE 1 DAY 1 | 24.667 Hour |
Secondary
Tmax for Belantamab Mafodotin (Total Antibody), Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 1.267 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 1.342 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 1.033 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 8 | 1.583 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment A | CYCLE 1 DAY 1 | 2.000 Hour |
Secondary
Tmax for Belantamab Mafodotin (Total Antibody), Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Cycle 1 Day 1 and Cycle 1 Day 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 1.900 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 2.033 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 0.983 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 1.142 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 0.700 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 2.000 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 1.983 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 0.650 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 8 | 0.617 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tmax for Belantamab Mafodotin (Total Antibody), Treatment B | CYCLE 1 DAY 1 | 2.000 Hour |
Secondary
Tmax for Bortezomib, Treatment B
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-dose, 5 minute, 0.25, 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 hour post bortezomib dose
Population: Pharmacokinetic (PK) population. Only those participants who received Bortezomib with data available at specified time points have been analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Bortezomib, Treatment B | Subcutaneous | 0.533 Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tmax for Bortezomib, Treatment B | Intravenous | NA Hour |
| Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex | Tmax for Bortezomib, Treatment B | Subcutaneous | 0.517 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tmax for Bortezomib, Treatment B | Intravenous | NA Hour |
| Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex | Tmax for Bortezomib, Treatment B | Subcutaneous | 0.500 Hour |
Secondary
Tmax for Lenalidomide (10 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 10 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Lenalidomide (10 mg), Treatment A | 2.000 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Lenalidomide (10 mg), Treatment A | NA Hour |
Secondary
Tmax for Lenalidomide (25 mg), Treatment A
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Pre-Dose, 0.5, 1, 2, 4 and 24 hours on Cycle 1 Day 1 post lenalidomide dose
Population: Pharmacokinetic (PK) population. Only those participants who received 25 mg lenalidomide with data available at specified time points have been analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Tmax for Lenalidomide (25 mg), Treatment A | 0.967 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Tmax for Lenalidomide (25 mg), Treatment A | 1.417 Hour |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Tmax for Lenalidomide (25 mg), Treatment A | 3.767 Hour |
Secondary
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A
Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.
Time frame: Cycle 1: Pre-Dose, 0, 2 and 24 Hours Post-Dose on Days 1 and 8; Weeks 5, 9, and 13: Pre-Dose and Post-Dose on Days 1 and 8
Population: Pharmacokinetic (PK) population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 1.79 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 3.52 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 8 | 1.17 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 8 | 1.30 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 8 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | 4.89 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | 5.05 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 8 | 2.03 ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 9 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 5 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | WEEK 13 DAY 1 | NA ug/mL |
| Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex | Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin ADC, Treatment A | CYCLE 1 DAY 1 | 1.08 ug/mL |